Viz.ai, a pioneer in AI-driven disease detection and intelligent care coordination, has been recognized once again at the prestigious 2025 Edison Awards. The company’s Viz HCM software — designed to detect and triage patients with signs of hypertrophic cardiomyopathy (HCM) — won in the Health Medical & Biotech category, under Cardiovascular Health Diagnostics and Monitoring. This marks the third consecutive Edison Award for Viz.ai, underscoring its sustained leadership in advancing AI solutions for life-saving medical innovation.
AI Innovation for an Underdiagnosed Condition
HCM is the most commonly inherited cardiac disease, yet it remains underdiagnosed in up to 85% of cases. Viz HCM is designed to close this critical gap by using AI to analyze 12-lead ECGs across entire health systems, identifying suspected HCM cases in real time.
Once detected, the platform notifies cardiology teams, accelerating patient follow-up and improving the likelihood of timely, accurate diagnosis.
“We are honored to win our third, prestigious Edison Award, reaffirming our mission-critical work to transform AI-driven healthcare,” said Dr. Chris Mansi, CEO and co-founder of Viz.ai. “The recognition of Viz HCM validates our commitment to helping clinicians deliver faster and better care for a disease that often goes unnoticed.”
Regulatory Milestone and Clinical Impact
The Viz HCM platform received De Novo approval from the FDA in August 2023, creating a new regulatory classification for machine learning-based cardiovascular notification tools. This milestone further cements Viz.ai’s pioneering role in defining how AI is integrated into clinical workflows.
In a recent study conducted at Cleveland Clinic, Viz HCM helped identify 574 patients with suspected HCM over a nine-month period — a significant advancement in real-world disease detection capability.
The solution was developed through a multi-year strategic partnership with Bristol Myers Squibb (NYSE: BMY), aimed at improving the identification and management of cardiovascular conditions.
Validation from a Premier Innovation Award
The Edison Awards are one of the most prestigious honors in product and service innovation. The judging process is rigorous, involving a review by the Edison Awards Steering Committee and an executive panel of 2,000+ senior industry leaders and academics across business, healthcare, engineering, and design.
Viz.ai’s continued recognition reflects its breakthrough contributions in the AI healthcare space and its mission to close care gaps through intelligent automation.
Shaping the Future of AI-Driven Cardiovascular Care
With Viz HCM, Viz.ai is reshaping how heart disease is detected, triaged, and treated, proving that AI can elevate both clinical performance and patient outcomes. The company’s third Edison Award signals not just consistent innovation but also growing trust in its technology to make a real difference in healthcare.
